Advertisement

Topics

US FDA approves AbbVie's imbruvica for treatment of adults with cGVHD

19:00 EDT 3 Aug 2017 | Pharmaceutical Technology

The US Food and Drug Administration (FDA) has expanded the approval of imbruvica (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after the failure of one or more treatments.

Original Article: US FDA approves AbbVie's imbruvica for treatment of adults with cGVHD

NEXT ARTICLE

More From BioPortfolio on "US FDA approves AbbVie's imbruvica for treatment of adults with cGVHD"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...